YiChang HEC ChangJiang Pharmaceutical Co Ltd Sustainability Reports
The company develops, manufactures, and sells pharmaceutical products in China, specializing in anti-viral, endocrine, and metabolic drugs. Its primary core product is the anti-influenza drug Kewei (Oseltamivir Phosphate).
Sector: Manufacturing
Country: China
Exchange: Hong Kong Stock Exchange
FIGI: BBG00BNKGQK8
11 reports from 2016 to 2024
- YiChang HEC ChangJiang Pharmaceutical Co Ltd 2024 Annual Report
- YiChang HEC ChangJiang Pharmaceutical Co Ltd 2024 Environmental, Social and Governance Report
- YiChang HEC ChangJiang Pharmaceutical Co Ltd 2023 Annual Report
- YiChang HEC ChangJiang Pharmaceutical Co Ltd 2023 Environmental, Social and Governance Report
- YiChang HEC ChangJiang Pharmaceutical Co Ltd 2022 Environmental, Social and Governance Report